Literature DB >> 15541213

Confusion about measuring central nervous system effects.

Helmut G Madersbacher1.   

Abstract

Anticholinergic therapy together with behavioral treatment are the main stays of treatment for the overactive bladder. Successful therapy and patient compliance depend very much on side effects. In the past, little attention has been paid to anticholinergic side effects in the central nervous system (CNS), which can be critical, especially for elderly patients. Incidence and intensity of CNS effects depend on the pharmacokinetic and pharmacodynamic properties that are decisive whether anticholinergics pass the blood-brain barrier as a result of passive and active transport mechanisms. To measure potential CNS side effects of anticholinergic drugs, rapid eye movement sleep analysis, quantitative-topographic electroencephalogram studies, and psychometric tests were performed. Structural changes in brain morphology resulting from anticholinergics also were analyzed in a post-mortem study.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15541213     DOI: 10.1007/s11934-004-0068-9

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  23 in total

Review 1.  Drug-induced cognitive impairment in the elderly.

Authors:  A R Moore; S T O'Keeffe
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

2.  Discussion: functional role of M(1), M(2), and M(3) muscarinic receptors in overactive bladder.

Authors:  Y Igawa
Journal:  Urology       Date:  2000-05       Impact factor: 2.649

3.  Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.

Authors:  A Todorova; B Vonderheid-Guth; W Dimpfel
Journal:  J Clin Pharmacol       Date:  2001-06       Impact factor: 3.126

4.  Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors.

Authors:  Keith R Edwards; Judy T O'Connor
Journal:  J Am Geriatr Soc       Date:  2002-06       Impact factor: 5.562

Review 5.  Functional expression and localization of P-glycoprotein at the blood brain barrier.

Authors:  Reina Bendayan; Gloria Lee; Moise Bendayan
Journal:  Microsc Res Tech       Date:  2002-06-01       Impact factor: 2.769

Review 6.  Modulation of drug transporters at the blood-brain barrier.

Authors:  Gert Fricker; David S Miller
Journal:  Pharmacology       Date:  2004-04       Impact factor: 2.547

7.  Oxybutynin and cognitive dysfunction.

Authors:  C A Donnellan; L Fook; P McDonald; J R Playfer
Journal:  BMJ       Date:  1997-11-22

8.  How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study.

Authors:  I Milsom; P Abrams; L Cardozo; R G Roberts; J Thüroff; A J Wein
Journal:  BJU Int       Date:  2001-06       Impact factor: 5.588

9.  Tolterodine: a safe and effective treatment for older patients with overactive bladder.

Authors:  J G Malone-Lee; J B Walsh; M F Maugourd
Journal:  J Am Geriatr Soc       Date:  2001-06       Impact factor: 5.562

10.  Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.

Authors:  R A Appell
Journal:  Urology       Date:  1997-12       Impact factor: 2.649

View more
  3 in total

Review 1.  [Oral anticholinergics in overactive bladder].

Authors:  H Madersbacher
Journal:  Urologe A       Date:  2006-07       Impact factor: 0.639

Review 2.  Clinical pharmacokinetics of trospium chloride.

Authors:  Oxana Doroshyenko; Alexander Jetter; Karl P Odenthal; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder.

Authors:  Michael B Chancellor; David R Staskin; Gary G Kay; Bobby W Sandage; Michael G Oefelein; Jack W Tsao
Journal:  Drugs Aging       Date:  2012-04-01       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.